Form 8-K


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2018

Vaxart, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-35285

 

59-1212264

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 






290 Utah Ave. Suite 200

South San Francisco, California 94080

(Address of principal executive offices) (Zip Code)

 

(650) 550-3500

(Registrants telephone number, including area code)


Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).  

Emerging growth company o  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

1


 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(a)


On November 17, 2018, Jan Leschly resigned from the Board of Directors (including the Nominating and Corporate Governance Committee) of Vaxart, Inc., effective immediately.  Mr. Leschly informed Vaxart that his decision to resign as a director was not due to any disagreements with Vaxart on any matter relating to Vaxarts operations, policies or practices.

2


 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.







 

 







 

 


 


 

VAXART, INC.

 

Dated: November 20, 2018

 


 

 

 






 

 

By:

 

/s/ Wouter W. Latour

 

 


 


 

Name:

 

Wouter W. Latour, M.D.

 

 


 


 

Title:

 

President and Chief Executive Officer

 

 

3